Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Mar 17

PMID 35296095

Authors

Brandie C Taylor

Justin M Balko

Affiliations

Soon will be listed here.

Abstract

Immunotherapy has become a key therapeutic strategy in the treatment of many cancers. As a result, research efforts have been aimed at understanding mechanisms of resistance to immunotherapy and how anti-tumor immune response can be therapeutically enhanced. It has been shown that tumor cell recognition by the immune system plays a key role in effective response to T cell targeting therapies in patients. One mechanism by which tumor cells can avoid immunosurveillance is through the downregulation of Major Histocompatibility Complex I (MHC-I). Downregulation of MHC-I has been described as a mechanism of intrinsic and acquired resistance to immunotherapy in patients with cancer. Depending on the mechanism, the downregulation of MHC-I can sometimes be therapeutically restored to aid in anti-tumor immunity. In this article, we will review current research in MHC-I downregulation and its impact on immunotherapy response in patients, as well as possible strategies for therapeutic upregulation of MHC-I.

Citing Articles

MHC-I upregulation by macbecin II in the solid tumors potentiates the effect of active immunotherapy.

Deshpande R, Wu K, Wu S, Tyagi A, Smith E, Kim J EMBO Mol Med. 2025; .

PMID: 40087501 DOI: 10.1038/s44321-025-00213-7.

Identification of TAP2 as a novel immune target in human cancers: insights from integrated bioinformatics and experimental approaches.

Yang L, Gui J, Sheng Y, Liu J, Wang C, Fang Z Eur J Med Res. 2025; 30(1):163.

PMID: 40075453 PMC: 11905508. DOI: 10.1186/s40001-025-02360-6.

Current advancement of immune function paradox of tumour-infiltrating cells and their immunotherapeutic targets: a mini-review.

Tom V, Jose A, Mallick S, Sasidharan A, Pawar R, Somayaji Y Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40063239 DOI: 10.1007/s00210-025-03985-4.

Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols.

Cottrell T, Lotze M, Ali A, Bifulco C, Capitini C, Chow L J Immunother Cancer. 2025; 13(3).

PMID: 40054999 PMC: 11891540. DOI: 10.1136/jitc-2024-010928.

Tetrandrine augments melanoma cell immunogenicity via dual inhibition of autophagic flux and proteasomal activity enhancing MHC-I presentation.

He L, Liu Y, Jiang J, Wang D, Li Y, Zeng S Acta Pharmacol Sin. 2025; .

PMID: 40016522 DOI: 10.1038/s41401-025-01507-9.

References

Cordon-Cardo C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L, Feldman M . Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res. 1991; 51(23 Pt 1):6372-80. View

Loi S, Dushyanthen S, Beavis P, Salgado R, Denkert C, Savas P . RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clin Cancer Res. 2015; 22(6):1499-509. PMC: 4794351. DOI: 10.1158/1078-0432.CCR-15-1125. View

Shionoya Y, Kanaseki T, Miyamoto S, Tokita S, Hongo A, Kikuchi Y . Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition. Oncoimmunology. 2017; 6(2):e1274476. PMC: 5353923. DOI: 10.1080/2162402X.2016.1274476. View

Ye Q, Shen Y, Wang X, Yang J, Miao F, Shen C . Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer. Tissue Antigens. 2009; 75(1):30-9. DOI: 10.1111/j.1399-0039.2009.01390.x. View

Burr M, Sparbier C, Chan K, Chan Y, Kersbergen A, Lam E . An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell. 2019; 36(4):385-401.e8. PMC: 6876280. DOI: 10.1016/j.ccell.2019.08.008. View

Zhao M, Sun Y, Jiang X, Liu L, Sun L . Promotion on NLRC5 upregulating MHC-I expression by IFN-γ in MHC-I-deficient breast cancer cells. Immunol Res. 2020; 67(6):497-504. DOI: 10.1007/s12026-019-09111-w. View

Alam A, Taye N, Patel S, Thube M, Mullick J, Shah V . SMAR1 favors immunosurveillance of cancer cells by modulating calnexin and MHC I expression. Neoplasia. 2019; 21(10):945-962. PMC: 6706529. DOI: 10.1016/j.neo.2019.07.002. View

Farina A, Tacconelli A, Cappabianca L, De Santis G, Gulino A, Mackay A . All-trans-retinoic acid induces nuclear factor kappaB activation and matrix metalloproteinase-9 expression and enhances basement membrane invasivity of differentiation-resistant human SK-N-BE 9N neuroblastoma Cells. Cell Growth Differ. 2002; 13(8):343-54. View

Cho S, Vijayan S, Yoo J, Watanabe T, Ouda R, An N . MHC class I transactivator NLRC5 in host immunity, cancer and beyond. Immunology. 2020; 162(3):252-261. PMC: 7884647. DOI: 10.1111/imm.13235. View

10.

Vinay D, Ryan E, Pawelec G, Talib W, Stagg J, Elkord E . Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015; 35 Suppl:S185-S198. DOI: 10.1016/j.semcancer.2015.03.004. View

11.

Kobayashi M, Nagashio R, Jiang S, Saito K, Tsuchiya B, Ryuge S . Calnexin is a novel sero-diagnostic marker for lung cancer. Lung Cancer. 2015; 90(2):342-5. DOI: 10.1016/j.lungcan.2015.08.015. View

12.

Shukla A, Cloutier M, Santharam M, Ramanathan S, Ilangumaran S . The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy. Int J Mol Sci. 2021; 22(4). PMC: 7922096. DOI: 10.3390/ijms22041964. View

13.

Propper D, Chao D, Braybrooke J, Bahl P, Thavasu P, Balkwill F . Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. Clin Cancer Res. 2003; 9(1):84-92. View

14.

Spel L, Nieuwenhuis J, Haarsma R, Stickel E, Bleijerveld O, Altelaar M . Nedd4-Binding Protein 1 and TNFAIP3-Interacting Protein 1 Control MHC-1 Display in Neuroblastoma. Cancer Res. 2018; 78(23):6621-6631. DOI: 10.1158/0008-5472.CAN-18-0545. View

15.

Yoshihama S, Cho S, Yeung J, Pan X, Lizee G, Konganti K . NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy. Sci Rep. 2021; 11(1):3258. PMC: 7865024. DOI: 10.1038/s41598-021-82729-9. View

16.

Seliger B, Hohne A, Knuth A, Bernhard H, Ehring B, Tampe R . Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin Cancer Res. 1996; 2(8):1427-33. View

17.

Mari L, Hoefnagel S, Zito D, van de Meent M, van Endert P, Calpe S . microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients. Gastroenterology. 2018; 155(3):784-798. DOI: 10.1053/j.gastro.2018.06.030. View

18.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

19.

McGranahan N, Swanton C . Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell. 2017; 168(4):613-628. DOI: 10.1016/j.cell.2017.01.018. View

20.

Sade-Feldman M, Jiao Y, Chen J, Rooney M, Barzily-Rokni M, Eliane J . Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017; 8(1):1136. PMC: 5656607. DOI: 10.1038/s41467-017-01062-w. View